In Vitro Study of Doxorubicin Nanomedicine for Gastric Cancer Cells

Abstract

In order to study the performance of doxorubicin nanomedicine on gastric cancer cells, the prepared mesoporous silica nanoparticle samples and the doxorubicin hydrochloride solution samples of different concentrations were synthesized and prepared to concentrations of 0.01 mg/ml and 0.03 mg/ml, 0.05 mg/ml, 0.07 mg/ml and 0.09 mg/ml respectively. Doxorubicin hydrochloride-loaded mesoporous silica nanoparticles samples were applied to the cultured gastric cancer cells. Through transmission electron microscope, specific surface area and pore size distribution analyzer, ultraviolet spectrophotometer and other instruments, test the morphology, surface area, pore volume and average pore size, drug release performance and adsorption of mesoporous silica nanoparticles samples loaded with doxorubicin hydrochloride- desorption performance, drug loading, drug loading and encapsulation rate, and gastric cancer cell survival rate, etc., so as to conduct in vitro research and analysis of doxorubicin drugs for gastric cancer cells. The test results show that mesoporous silica nanoparticles samples are suitable for drug delivery, with high drug loading and encapsulation rate and drug controlled release effect as the acidity of the buffer increases, it is beneficial to the release of drugs in the slightly acidic environment of the tumor site; mesoporous silica nanoparticles, the drug loading of the sample after three times of ultrafiltration is about 55 % and the encapsulation efficiency is above 90 %; as the sample concentration increases, the survival rate of gastric cancer cells gradually decreases. This shows that doxorubicin nanomedicine can be used to inhibit gastric cancer cells and can assist in the treatment of gastric cancer.